伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松治疗新诊断适合移植的多发性骨髓瘤患者(SKylaRk):一项单臂2期试验
这项单臂2期试验在波士顿三个癌症中心纳入50例适合移植的新诊断多发性骨髓瘤患者,接受Isa-KRd方案治疗,按细胞遗传学风险分层维持治疗。主要终点四周期后完全缓解率为32%,未达到预设阈值;总缓解率90%,巩固治疗后完全缓解率58%。方案安全性可控,与类似方案一致。
要点
- 四周期Isa-KRd后完全缓解率为32%(16/50),未达到预设阈值
- 巩固治疗后完全缓解率58%(29/50),总缓解率90%(45/50)
- 最常见3-4级不良事件为中性粒细胞减少(26%)、丙氨酸氨基转移酶升高(12%)
核心结论
- 尽管研究未达到预设的完全缓解阈值,Isa-KRd在新诊断适合移植的多发性骨髓瘤患者中诱导了深度且持久的缓解。
研究设计与样本
- 单臂2期试验,在波士顿三个癌症中心(两家医院和一家癌症研究所)进行。
- 纳入50例年龄≥18岁、适合移植的新诊断多发性骨髓瘤患者,ECOG体能状态评分≤2。
- 患者接受四个28天周期的Isa-KRd治疗,巩固治疗为 upfront 造血干细胞移植(HSCT)加两个额外周期或延迟HSCT加四个额外周期。
- 主要终点为四周期治疗后的完全缓解,分析按意向性治疗进行。
主要发现
- 中位年龄59岁(范围40-70),54%(27/50)为男性,44例(88%)为白人,46%(23/50)具有高危细胞遗传学。
- 中位随访26个月(IQR 20.7-30.1),四周期后32%(16/50)达到完全缓解,总缓解率90%(45例),78%(39例)达到非常好的部分缓解(VGPR)或更好。
- 巩固治疗完成后,58%(29例)达到完全缓解,总缓解率90%(45例),86%(43例)达到VGPR或更好。
- 最常见的3级或4级副作用(≥2例患者)包括中性粒细胞减少(13例[26%])、丙氨酸氨基转移酶升高(6例[12%])、疲乏(3例[6%])、血小板减少(3例[6%])、急性肾损伤(2例[4%])、贫血(2例[4%])和发热性中性粒细胞减少(2例[4%])。
- 1-2级输注相关反应见于20%(10例),无3级;1-2级高血压见于14%(7例),3级1例(2%);两例死亡评估为与治疗无关。
关键数值与推荐
- Isa-KRd方案:伊沙妥昔单抗10 mg/kg静脉给药,前8周每周一次,之后每2周一次持续16周,此后每4周一次;卡非佐米56 mg/m2静脉给药,第1、8、15天(第1周期第1天为20 mg/m2);来那度胺25 mg口服,第1-21天;地塞米松20 mg口服,在所有卡非佐米和伊沙妥昔单抗给药当天及次日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk. METHODS: This single-arm phase 2 trial was done at three cancer centres (two hospitals and a cancer institute) in Boston (MA, USA). Eligible patients were aged at least 18 years and had transplant-eligible newly diagnosed multiple myeloma and an ECOG performance status of 2 or less. Patients received four 28-day cycles of Isa-KRd, including isatuximab 10 mg/kg intravenously weekly for 8 weeks, then every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m2 intravenously on days 1, 8, and 15 (20 mg/m2 for cycle 1 day 1); lenalidomide 25 mg orally on days 1-21; and dexamethasone 20 mg orally the day of and day after all doses of carfilzomib and isatuximab. Consolidation involved either upfront haematopoietic stem-cell transplantation (HSCT) with two additional cycles or deferred HSCT with four additional cycles of treatment. The primary endpoint was complete response after four cycles of treatment. Analyses were by intention-to-treat. All patients who received one dose of study drug were included in the safety analyses. This study was registered at ClinicalTrials.gov, NCT04430894, and has completed enrolment. FINDINGS: Between July 31, 2020 and Jan 31, 2022, 50 patients were enrolled. Median age was 59 years (range 40-70), 54% (27 of 50 patients) were male, and 44 (88%) were White. 46% (23 of 50) of patients had high-risk cytogenetics. Median follow-up was 26 months (IQR 20·7-30·1). 32% (16 of 50 patients) achieved a complete response after four cycles. The overall response rate (ORR) was 90% (45 patients) and 78% (39 patients) achieved a very good partial response (VGPR) or better. After completion of consolidation, 58% (29 patients) achieved a complete response; the ORR was 90% (45 patients) and 86% (43 patients) achieved a VGPR or better. The most common grade 3 or 4 side-effects (≥two patients) included neutropenia (13 [26%] of 50 patients), elevated alanine aminotransferase (six [12%] patients), fatigue (three [6%] patients), thrombocytopenia (three [6%] patients), acute kidney injury (two [4%] patients), anaemia (two [4%] patients), and febrile neutropenia (two [4%] patients). Grade 1-2 infusion-related reactions were seen in 20% (ten patients), with none grade 3. Grade 1-2 hypertension was seen in 14% (seven patients) with one grade 3 (one [2%] patient). There were two deaths assessed as unrelated to treatment. INTERPRETATION: Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting. FUNDING: Amgen, Sanofi, and Adaptive.
引用
- O'Donnell E, Mo C, Yee AJ, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial. Lancet Haematol. 2024. PMID: 38677302. doi:10.1016/S2352-3026(24)00070-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。